SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bajaj Healthcare shines on getting EIR from USFDA for API manufacturing facility in Gujarat

14 Sep 2023 Evaluate

Bajaj Healthcare is currently trading at Rs. 431.15, up by 17.75 points or 4.29% from its previous closing of Rs. 413.40 on the BSE.

The scrip opened at Rs. 428.15 and has touched a high and low of Rs. 448.00 and Rs. 424.85 respectively. So far 56756 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 457.55 on 02-Jan-2023 and a 52 week low of Rs. 245.05 on 31-May-2023.

Last one week high and low of the scrip stood at Rs. 448.00 and Rs. 373.45 respectively. The current market cap of the company is Rs. 1140.92 crore.

The promoters holding in the company stood at 67.49%, while Institutions and Non-Institutions held 1.03% and 31.48% respectively.

Bajaj Healthcare has received Establishment Inspection Report (EIR) from the United State Food and Drug Administration (USFDA), for the Pre-approval inspection that was carried out by the USFDA in November, 2022 at its API manufacturing facility in Savli, Vadodara, Gujarat, with Zero 483 observations (No inspectional observations).

The receipt of the Establishment Inspection Report signifies the successful conclusion of the inspection. It serves as a testament to its dedication to upholding global standards of quality and compliance

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries. 

Bajaj Healthcare Share Price

348.95 -1.50 (-0.43%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×